Market Cap
$9.6M
TOVX
Theriva Biologics, Inc.
$0.2361 ▲ +2.65%
Prev close $0.2300Market cap$9.6M
12-mo target$2.50 (+958.9%)
High Impact Filing (7/10)3 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on TOVX right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
16 funds
Inst. Value
$407.5K
Inst. Activity
3 buys / 2 sells
Social Sentiment
50° Neutral
SEC Reports
6
Press Releases
2
Price chart 30d -5.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 27, 2026 short_volume
Aug 11, 2026 SEC Short Volume: TOVX — 64.0% short (0.6M / 1.0M)
Short: 612,377 | Exempt: 2,712 | TRF Vol: 956,307 | Short Ratio: 64.0% | Off-exchange volume (dark p
Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07/share), compared to a $13.1M loss (
8-K — Impact 4/10
Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07 per share) vs $13.1M ($1.93 per sha
PRESS-RELEASE — Impact 5/10
Theriva Biologics held its 2026 Annual Meeting on August 3, 2026, where stockholders approved all six proposals, includi
8-K — Impact 4/10
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — DOUBLED
486,179 shares ($121.5K)
Jun 30, 2026 Inst.
Jun 11, 2026 Press JANE STREET GROUP, LLC — ADD
331,922 shares ($83.0K)
Theriva Biologics announced publication of Phase 1 trial results for VCN-01 in immunotherapy-refractory HNSCC in Clinica
Impact 7/10
Theriva Biologics reported its 2025 financial results, highlighted by a $9.0 million contingent consideration charge tie
Impact 6/10
Analyst ratings buy % +17.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Mar 31, 2026 | Maxim Group | UPGRADE | Buy | 43% |
| May 8, 2025 | Maxim Group | DOWNGRADE | Hold | 43% |
| Nov 13, 2024 | Maxim Group | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Aug 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jul 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% |
Price targets
Where 2 covering analysts think TOVX trades over the next 12 months.
$2.50 +958.9% upside Strong Buy
Current$0.2361 Low$1.00 Median$2.50 High$4.00 2 analysts
$1.00$4.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood -12.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
$TOVX possible triggered Short?
▲ 1 · 💬 0· ⚡ 0.5
TOVX No shares for warrants = no shares for offerings Warrants at .54
▲ 1 · 💬 1· ⚡ 0.4
TOVX - Theriva Biologics Inc.
▲ 1 · 💬 1· ⚡ 0.5
TOVX - Theriva Biologics Inc
▲ 1 · 💬 0· ⚡ 0.5
20 APRIL 2026, WHAT ARE THE BIGGEST WINNERS PRE-MARKET AN WHY ?
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 2 bullish, 1 bearish, 1 mixed, 2 neutral · avg impact 5.2/10.Plus 2 press releases.
NEUTRAL8-K4/10
Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07/share), compare
Aug 11, 2026
NEUTRALPRESS-RELEASE5/10
Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07 per share) vs $
Aug 11, 2026
BEARISH8-K4/10
Theriva Biologics held its 2026 Annual Meeting on August 3, 2026, where stockholders approved all si
Aug 4, 2026
BULLISH8-K5/10
Theriva Biologics received regulatory authorization from the Spanish AEMPS to initiate the VIRAGE2 P
Jul 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 27, 2026
short_volume
Short Volume: TOVX — 64.0% short (0.6M / 1.0M)
Short: 612,377 | Exempt: 2,712 | TRF Vol: 956,307 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Aug 19, 2026
short_volume
Short Volume: TOVX — 58.0% short (0.3M / 0.5M)
Short: 292,139 | Exempt: 0 | TRF Vol: 503,429 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
Aug 11, 2026
earnings
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal
Aug 10, 2026
earnings_calendar
TOVX Q2 2026 Earnings Scheduled — 2026-08-10
Aug 6, 2026
other
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metast
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.06 | $-0.06–$-0.06 | 86.7% | -20.0% | 0↑ 1↓ | $0.0B | 1 |
| Next Q | $-0.06 | $-0.06–$-0.06 | — | -20.0% | 0↑ 1↓ | $0.0B | 1 |
| Current FY | $-0.25 | $-0.25–$-0.25 | 88.0% | -25.0% | 0↑ 1↓ | $0.0B | 1 |
| Next FY | $-0.20 | $-0.20–$-0.20 | 20.0% | +0.0% | 1↑ 0↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.060 | — |
| 7d ago | $-0.050 | -0.010 |
| 30d ago | $-0.050 | -0.010 |
| 60d ago | $-0.050 | -0.010 |
| 90d ago | $-0.050 | -0.010 |
Institutional ownership
Which big funds own TOVX (from quarterly 13F filings) and who is adding or trimming.
16 institutional holders with $407.5K total value (1,629,234 shares) as of 2026-Q2. Top holders: DANSKE, ROYAL, VANGUARD. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| DANSKE BANK A/S | 1 | $0.00 | 0.0% | — |
| ROYAL BANK OF CANADA | 1 | $0.00 | 0.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 486,179 | $121.5K | 29.8% | DOUBLED +152.7% |
| JANE STREET GROUP, LLC | 331,922 | $83.0K | 20.4% | ADD +87.5% |
| GEODE CAPITAL MANAGEMENT, LLC | 294,021 | $73.6K | 18.1% | TRIM -34.7% |
| VANGUARD FIDUCIARY TRUST CO | 241,780 | $60.4K | 14.8% | — |
| NORTHERN TRUST CORP | 82,700 | $20.7K | 5.1% | — |
| RENAISSANCE TECHNOLOGIES LLC | 63,710 | $15.9K | 3.9% | — |
| UBS Group AG | 61,053 | $15.3K | 3.7% | TRIM -72.9% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 24,064 | $6.0K | 1.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | 192,404 | 486,179 | +152.7% | $121.5K |
| JANE STREET GROUP, LLC | ADD | 177,034 | 331,922 | +87.5% | $83.0K |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | 450,263 | 294,021 | -34.7% | $73.6K |
| UBS Group AG | TRIM | 225,624 | 61,053 | -72.9% | $15.3K |
| OSAIC HOLDINGS, INC. | DOUBLED | 8 | 441 | +5412.5% | $110.00 |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 212,087 | 450,263 | +112.3% | $88.2K |
| MORGAN STANLEY | NEAR_EXIT | 200,000 | 23,602 | -88.2% | $4.6K |
| OSAIC HOLDINGS, INC. | NEAR_EXIT | 448 | 8 | -98.2% | $1.00 |
| VANGUARD GROUP INC | DOUBLED | 16,382 | 255,727 | +1461.0% | $53.7K |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 28,209 | 212,087 | +651.8% | $44.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TOVX.
Shares short
1,589,504
Settlement Sep 15, 2026
Change vs prior
-9.9%
Semi-monthly cycle
Days to cover
3.1
At avg daily volume
Of shares outstanding
≈3.5%
Estimate — not % of float
All TOVX filing & press-release reports (8)
- 8-K reportAug 11, 2026
- PRESS-RELEASE reportAug 11, 2026
- 8-K reportAug 4, 2026
- 8-K reportJul 7, 2026
- PRESS-RELEASE reportJun 11, 2026
- 8-K reportApr 17, 2026
- 8-K reportMar 12, 2026
- PRESS-RELEASE reportMar 12, 2026